EP 1513864 A4 20060405 - THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF USE
Title (en)
THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF USE
Title (de)
THERAPEUTISCHE POLYPEPTIDE, DIESE CODIERENDE NUKLEINSÄUREN UND VERWENDUNGSVERFAHREN
Title (fr)
POLYPEPTIDES THERAPEUTIQUES, ACIDES NUCLEIQUES CODANT CES DERNIERS ET LEURS PROCEDES D'UTILISATION
Publication
Application
Priority
- US 0303403 W 20030203
- US 35509902 P 20020208
- US 7497802 A 20020212
- US 35642402 P 20020212
- US 35792802 P 20020219
- US 35860802 P 20020221
- US 35986002 P 20020227
- US 37557902 P 20020425
- US 13858802 A 20020501
- US 38166602 P 20020517
- US 38700202 P 20020607
- US 39326502 P 20020702
- US 40182502 P 20020807
Abstract (en)
[origin: WO03066881A2] Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
IPC 1-7
IPC 8 full level
G01N 33/50 (2006.01); A61K 31/7088 (2006.01); A61K 38/00 (2006.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); A61P 1/04 (2006.01); A61P 1/14 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 7/00 (2006.01); A61P 7/04 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 11/06 (2006.01); A61P 19/00 (2006.01); A61P 25/00 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 31/00 (2006.01); A61P 31/18 (2006.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); A61P 37/04 (2006.01); A61P 37/06 (2006.01); A61P 37/08 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 15/09 (2006.01); C12P 21/02 (2006.01); C12Q 1/02 (2006.01); C12Q 1/68 (2006.01); G01N 33/15 (2006.01); G01N 33/53 (2006.01); G01N 33/566 (2006.01)
CPC (source: EP)
A61P 1/04 (2017.12); A61P 1/14 (2017.12); A61P 3/00 (2017.12); A61P 3/04 (2017.12); A61P 3/06 (2017.12); A61P 3/10 (2017.12); A61P 7/00 (2017.12); A61P 7/04 (2017.12); A61P 9/00 (2017.12); A61P 9/10 (2017.12); A61P 9/12 (2017.12); A61P 11/06 (2017.12); A61P 19/00 (2017.12); A61P 25/00 (2017.12); A61P 25/16 (2017.12); A61P 25/18 (2017.12); A61P 25/24 (2017.12); A61P 25/28 (2017.12); A61P 31/00 (2017.12); A61P 31/18 (2017.12); A61P 35/00 (2017.12); A61P 37/02 (2017.12); A61P 37/04 (2017.12); A61P 37/06 (2017.12); A61P 37/08 (2017.12); C07K 14/47 (2013.01)
Citation (search report)
- [X] WO 0005374 A2 20000203 - INCYTE PHARMA INC [US], et al
- [A] WO 0129217 A2 20010426 - CURAGEN CORP [US], et al
- See references of WO 03066881A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR
DOCDB simple family (publication)
WO 03066881 A2 20030814; WO 03066881 A3 20050120; AU 2003215010 A1 20030902; EP 1513864 A2 20050316; EP 1513864 A4 20060405; JP 2005518200 A 20050623
DOCDB simple family (application)
US 0303403 W 20030203; AU 2003215010 A 20030203; EP 03710863 A 20030203; JP 2003566229 A 20030203